MyFinsight
Home
Blog
About
Proceeds from exercise of
stock options
$7,523K
(204.08%↑ Y/Y)
Net cash provided by
(used in) financing...
$7,523K
(-98.41%↓ Y/Y)
Net change in cash,
cash equivalents and...
-$68,448K
(-4985.29%↓ Y/Y)
Canceled cashflow
$7,523K
Prepaid expenses and
other current assets
-$29,533K
(-944.68%↓ Y/Y)
Stock-based compensation
expense
$19,278K
(-62.24%↓ Y/Y)
Depreciation and
amortization
$5,410K
(-51.11%↓ Y/Y)
Change in fair value of
derivative liabilities
-$4,200K
(-223.28%↓ Y/Y)
Change in operating
lease right-of-use...
$2,561K
(-51.65%↓ Y/Y)
Accrued expenses and
other liabilities
$1,315K
(115.31%↑ Y/Y)
Accounts payable
$1,214K
(-81.13%↓ Y/Y)
Change in fair value of
contingent consideration...
$205K
(272.73%↑ Y/Y)
Amortization of debt discount
$64K
Loss (gain) on
disposal of property and...
-$44K
Maturities of marketable
securities
$173,000K
(-54.93%↓ Y/Y)
Proceeds from sale of
equity method...
$455K
Net cash provided by
(used in) operating...
-$66,096K
(63.35%↑ Y/Y)
Net cash provided by
(used in) investing...
-$9,875K
(96.66%↑ Y/Y)
Canceled cashflow
$63,824K
Canceled cashflow
$173,455K
Interest and other income
$7,487K
License and
collaboration revenue
$490K
Net loss
-$122,678K
(42.01%↑ Y/Y)
Purchases of marketable
securities
$180,916K
(-73.12%↓ Y/Y)
Canceled cashflow
$7,977K
Operating lease
liabilities
-$3,529K
(46.71%↑ Y/Y)
Amortization of investment
discount (premiums)
$2,605K
(-69.23%↓ Y/Y)
Gain on sale of equity
method investment
$455K
Change in fair value of
non-controlling equity...
$338K
(-85.52%↓ Y/Y)
Deferred revenue
-$304K
(98.09%↑ Y/Y)
Other long-term
liabilities
-$11K
(92.47%↑ Y/Y)
Purchases of property and
equipment
$2,414K
(-61.07%↓ Y/Y)
Research and development
expenses-Employee Related...
$31,955K
Research and development
expenses-External Research And...
$31,566K
Stock-based compensation
$19,278K
Facility and information
technology related...
$15,441K
General and
administrative...
$12,703K
General and
administrative...
$9,561K
Depreciation and
amortization
$5,410K
(-51.11%↓ Y/Y)
Other segment items
$4,741K
Back
Back
Cash Flow
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)
source: myfinsight.com